AU2020367014A1 - B-lymphocyte specific amatoxin antibody conjugates - Google Patents

B-lymphocyte specific amatoxin antibody conjugates Download PDF

Info

Publication number
AU2020367014A1
AU2020367014A1 AU2020367014A AU2020367014A AU2020367014A1 AU 2020367014 A1 AU2020367014 A1 AU 2020367014A1 AU 2020367014 A AU2020367014 A AU 2020367014A AU 2020367014 A AU2020367014 A AU 2020367014A AU 2020367014 A1 AU2020367014 A1 AU 2020367014A1
Authority
AU
Australia
Prior art keywords
antibody
amatoxin
conjugate
linker
rituximab
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020367014A
Other languages
English (en)
Inventor
Torsten HECHLER
Michael Kulke
Christoph Müller
Andreas Pahl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Heidelberg Pharma Research GmbH
Original Assignee
Heidelberg Pharma Research GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heidelberg Pharma Research GmbH filed Critical Heidelberg Pharma Research GmbH
Publication of AU2020367014A1 publication Critical patent/AU2020367014A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6831—Fungal toxins, e.g. alpha sarcine, mitogillin, zinniol or restrictocin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
AU2020367014A 2019-10-15 2020-10-15 B-lymphocyte specific amatoxin antibody conjugates Pending AU2020367014A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19203400 2019-10-15
EP19203400.7 2019-10-15
PCT/EP2020/078979 WO2021074261A1 (en) 2019-10-15 2020-10-15 B-lymphocyte specific amatoxin antibody conjugates

Publications (1)

Publication Number Publication Date
AU2020367014A1 true AU2020367014A1 (en) 2022-04-14

Family

ID=68281092

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020367014A Pending AU2020367014A1 (en) 2019-10-15 2020-10-15 B-lymphocyte specific amatoxin antibody conjugates

Country Status (12)

Country Link
EP (1) EP4045091A1 (ja)
JP (1) JP2022552349A (ja)
KR (1) KR20220082846A (ja)
CN (1) CN114845737A (ja)
AR (1) AR120218A1 (ja)
AU (1) AU2020367014A1 (ja)
BR (1) BR112022006283A2 (ja)
CA (1) CA3151578A1 (ja)
CO (1) CO2022004606A2 (ja)
IL (1) IL291581A (ja)
MX (1) MX2022004416A (ja)
WO (1) WO2021074261A1 (ja)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3192529T1 (sl) * 2009-04-08 2020-07-31 Faulstich, Heinz Dr. Z amatoksinom ojačane vezne komponente terapevtske celične površine, zasnovane za zdravljenje tumorjev
ES2402254T3 (es) * 2010-09-30 2013-04-30 Heidelberg Pharma Ag Conjugados de amatoxinas con ligadores mejorados
US20150218220A1 (en) * 2012-09-12 2015-08-06 Brian Alan MENDELSOHN Amatoxin derivatives and cell-permeable conjugates thereof as inhibitors of rna polymerase
WO2016071856A1 (en) * 2014-11-06 2016-05-12 Novartis Ag Amatoxin derivatives and conjugates thereof as inhibitors of rna polymerase
JP6863900B2 (ja) * 2015-03-09 2021-04-21 ハイデルベルク ファルマ リサーチ ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規アマトキシン−抗体コンジュゲート
US11413353B2 (en) * 2015-11-25 2022-08-16 Legochem Biosciences, Inc. Conjugates comprising self-immolative groups and methods related thereto
EP3222292A1 (en) * 2016-03-03 2017-09-27 Heidelberg Pharma GmbH Amanitin conjugates
BR112018071465A2 (pt) * 2016-04-20 2019-02-05 Hangzhou Dac Biotech Co Ltd derivados de toxinas de amanita e sua conjugação a uma molécula de ligação celular
MX2019007604A (es) * 2016-12-23 2019-08-16 Heidelberg Pharma Res Gmbh Novedoso conjugado de amanitina.
CA3076289A1 (en) * 2017-09-22 2019-03-28 Heidelberg Pharma Research Gmbh Psma-targeting amanitin conjugates
US10882915B2 (en) * 2017-10-24 2021-01-05 Magenta Therapeutics, Inc. Compositions and methods for the depletion of CD117+ cells

Also Published As

Publication number Publication date
KR20220082846A (ko) 2022-06-17
MX2022004416A (es) 2022-05-24
CO2022004606A2 (es) 2022-07-08
AR120218A1 (es) 2022-02-02
EP4045091A1 (en) 2022-08-24
IL291581A (en) 2022-05-01
CA3151578A1 (en) 2021-04-22
CN114845737A (zh) 2022-08-02
WO2021074261A1 (en) 2021-04-22
JP2022552349A (ja) 2022-12-15
BR112022006283A2 (pt) 2022-06-21

Similar Documents

Publication Publication Date Title
US20210128742A1 (en) CD123 Antibodies and Conjugates Thereof
JP7423513B2 (ja) 抗葉酸受容体α抗体コンジュゲート及びその使用
KR102419766B1 (ko) 항체에 대한 링커 약물의 부위 특이적 접합 및 그 결과로 얻어지는 adc
AU2019272250B2 (en) Anti-mesothelin antibody and antibody-drug conjugate thereof
JP6892826B2 (ja) Ｃｄ４８抗体及びその複合体
CN105980411B (zh) 抗体-药物缀合物和免疫毒素
US20210061916A1 (en) Anti-prlr antibody-drug conjugates (adc) and uses thereof
TW202203978A (zh) 電荷可變連接子
US20210283267A1 (en) Therapeutic methods using antibody drug conjugates (adcs)
US20220089772A1 (en) Anti-glyco-muc1 antibodies and their uses
CN112020519A (zh) 抗her2双互补位抗体-药物偶联物及使用方法
CN107849146A (zh) 卡奇霉素构建体和使用方法
WO2019046859A1 (en) ANTI-EGFR-DRUG ANTIBODY (ADC) CONJUGATES AND USES THEREOF
TW202133885A (zh) 利用與191p4d12蛋白結合之抗體藥物結合物(adc)治療癌症
US20220370632A1 (en) B-lymphocyte specific amatoxin antibody conjugates
AU2020367014A1 (en) B-lymphocyte specific amatoxin antibody conjugates
KR20230104653A (ko) 암 요법에 사용하기 위한 면역 체크포인트 억제제 및 항체-아마톡신 접합체의 조합물을 포함하는 조성물
AU2017436815A1 (en) Anti-glyco-muc1 antibodies and their uses
RU2806049C9 (ru) Конъюгаты анти-her2 бипаратопных антител-лекарственных веществ и способы их применения
US20220133902A1 (en) Composition Comprising a Combination of Immune Checkpoint Inhibitor and Antibody-Amatoxin Conjugate for Use in Cancer Therapy
RU2806049C2 (ru) Конъюгаты анти-her2 бипаратопных антител-лекарственных веществ и способы их применения
TW202345907A (zh) 抗gd2抗體、其免疫結合物及治療用途